Amanda A. Bouffard

2.4k total citations · 2 hit papers
29 papers, 1.6k citations indexed

About

Amanda A. Bouffard is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Amanda A. Bouffard has authored 29 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 13 papers in Molecular Biology and 8 papers in Immunology. Recurrent topics in Amanda A. Bouffard's work include CAR-T cell therapy research (29 papers), CRISPR and Genetic Engineering (7 papers) and Nanowire Synthesis and Applications (6 papers). Amanda A. Bouffard is often cited by papers focused on CAR-T cell therapy research (29 papers), CRISPR and Genetic Engineering (7 papers) and Nanowire Synthesis and Applications (6 papers). Amanda A. Bouffard collaborates with scholars based in United States, Denmark and Germany. Amanda A. Bouffard's co-authors include Marcela V. Maus, Rebecca C. Larson, Irene Scarfò, Andrea Schmidts, Ana P. Castaño, Mark B. Leick, Matthew J. Frigault, Bryan D. Choi, Stefanie R. Bailey and Bob S. Carter and has published in prestigious journals such as Nature, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Amanda A. Bouffard

25 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

2019 426 citations Bryan D. Choi, Xiaoling Yu et al. Nature Biotechnology profile →
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours

2022 225 citations Rebecca C. Larson, Michael C. Kann et al. Nature profile →

Peers

Countries citing papers authored by Amanda A. Bouffard

Since Specialization

Citations

This map shows the geographic impact of Amanda A. Bouffard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda A. Bouffard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda A. Bouffard more than expected).

Fields of papers citing papers by Amanda A. Bouffard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda A. Bouffard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda A. Bouffard. The network helps show where Amanda A. Bouffard may publish in the future.

Co-authorship network of co-authors of Amanda A. Bouffard

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda A. Bouffard. A scholar is included among the top collaborators of Amanda A. Bouffard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda A. Bouffard. Amanda A. Bouffard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models 2025 ·Nature Communications ·(unknown), (unknown), (unknown), Amanda A. Bouffard, (unknown), (unknown), (unknown), Mark B. Leick, Nicholas J. Haradhvala, (unknown), Gad Getz, Giulia Escobar, Diego Salas‐Benito, Adele Mucci, Trisha R. Berger, Marcela V. Maus	0
2	Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer 2025 ·Nature Communications ·Sangwoo Park, Christine Ho, Eli P. Darnell, A Wolff, (unknown), (unknown), Amanda A. Bouffard, Diego Salas‐Benito, Giulia Escobar, Mark B. Leick, Adele Mucci, Trisha R. Berger, Marcela V. Maus	0
3	Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time 2025 ·Journal for ImmunoTherapy of Cancer ·Diego Salas‐Benito, (unknown), Sangwoo Park, Christine Ho, (unknown), (unknown), Amanda A. Bouffard, (unknown), Eugene Kim, (unknown), (unknown), (unknown), (unknown), Mark B. Leick, Giulia Escobar, Bo R. Rueda, Trisha R. Berger, Marcela V. Maus	0
4	Stealth transgenes enable CAR-T cells to evade host immune responses 2024 ·Journal for ImmunoTherapy of Cancer ·Korneel Grauwet, Trisha R. Berger, Michael C. Kann, (unknown), Rebecca C. Larson, Mark B. Leick, Stefanie R. Bailey, Amanda A. Bouffard, David G. Millar, Kathleen Gallagher, Cameron J. Turtle, Matthew J. Frigault, Marcela V. Maus	8
5	Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics 2024 ·Science Translational Medicine ·Felix Korell, Michael Olson, Diego Salas‐Benito, Mark B. Leick, Rebecca C. Larson, Amanda A. Bouffard, Harrison Silva, (unknown), Trisha R. Berger, Michael C. Kann, (unknown), (unknown), Marc Wehrli, Nicholas J. Haradhvala, Stefanie R. Bailey, Anthony Letai, Marcela V. Maus	14
6	CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML 2024 ·Blood ·Harrison Silva, (unknown), (unknown), Marc Wehrli, Michael C. Kann, (unknown), (unknown), Charlotte Graham, (unknown), Amanda A. Bouffard, (unknown), Giulia Escobar, (unknown), (unknown), (unknown), Trisha R. Berger, Bryan D. Choi, Marcela V. Maus, Mark B. Leick	11
7	Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma 2023 ·Nature Communications ·Rebecca C. Larson, Michael C. Kann, Charlotte Graham, Christopher Mount, Ana P. Castaño, Won‐Ho Lee, Amanda A. Bouffard, (unknown), (unknown), Irene Scarfò, Trisha R. Berger, Andrea Schmidts, Matthew J. Frigault, Kathleen Gallagher, Marcela V. Maus	23
8	Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7 2023 ·Leukemia ·Michael C. Kann, Emily M. Schneider, (unknown), (unknown), Amanda A. Bouffard, (unknown), (unknown), Alexander Tepper, Mark B. Leick, Rebecca C. Larson, Benjamin L. Ebert, Marcela V. Maus, Max Jan	4
9	Genetic retargeting of E3 ligases to enhance CAR T cell therapy 2023 ·Cell chemical biology ·(unknown), Gabriele Kembuan, (unknown), Michael C. Kann, William M. Lin, Amanda A. Bouffard, Johannes Kreuzer, Robert Morris, Emily M. Schneider, (unknown), Charles Zou, Diego Salas‐Benito, Jessica A. Gasser, Mark B. Leick, Mikołaj Słabicki, Wilhelm Haas, Marcela V. Maus, Max Jan	7
10	Abstract 4098: Chimeric antigen receptor (CAR) T cells overexpressing Bcl-xL increase proliferation and antitumor activity alone and in combination with BH3 mimetics 2023 ·Cancer Research ·Felix Korell, Michael Olson, Diego Salas‐Benito, Mark B. Leick, Rebecca C. Larson, Harrison Silva, (unknown), Trisha R. Berger, Amanda A. Bouffard, Michael C. Kann, (unknown), (unknown), Marc Wehrli, Stefanie R. Bailey, (unknown), Marcela V. Maus	3
11	CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours breakdown → 2022 ·Nature ·Rebecca C. Larson, Michael C. Kann, Stefanie R. Bailey, Nicholas J. Haradhvala, Paula Montero Llopis, Amanda A. Bouffard, Irene Scarfò, Mark B. Leick, Korneel Grauwet, Trisha R. Berger, (unknown), Praju Vikas Anekal, Max Jan, Julia Joung, Andrea Schmidts, Tamara Ouspenskaia, Travis Law, Aviv Regev, Gad Getz, Marcela V. Maus	225
12	Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia 2022 ·Cancer Cell ·Mark B. Leick, Harrison Silva, Irene Scarfò, Rebecca C. Larson, Bryan D. Choi, Amanda A. Bouffard, Kathleen Gallagher, Andrea Schmidts, Stefanie R. Bailey, Michael C. Kann, Max Jan, Marc Wehrli, Korneel Grauwet, Nora Horick, Matthew J. Frigault, Marcela V. Maus	88
13	Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide 2021 ·Science Translational Medicine ·Max Jan, Irene Scarfò, Rebecca C. Larson, (unknown), Andrea Schmidts, Andrew A. Guirguis, Jessica A. Gasser, Mikołaj Słabicki, Amanda A. Bouffard, Ana P. Castaño, Michael C. Kann, Maria L. Cabral, Alexander Tepper, (unknown), Adam S. Sperling, Taeyoon Kyung, Quinlan Sievers, Michael E. Birnbaum, Marcela V. Maus, Benjamin L. Ebert	180
14	Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources 2020 ·Journal for ImmunoTherapy of Cancer ·Andrea Schmidts, (unknown), (unknown), Amanda A. Bouffard, Angela C. Boroughs, Irene Scarfò, Rebecca C. Larson, Felipe Bedoya, Bryan D. Choi, Matthew J. Frigault, Stefanie R. Bailey, Mark B. Leick, (unknown), Michael C. Kann, Michelle S. Prew, Benjamin P. Kleinstiver, J. Keith Joung, Marcela V. Maus	18
15	Bispecific CAR T cells for multiple myeloma: natural ligand compared to tandem scFv design 2020 ·The Journal of Immunology ·Rebecca C. Larson, Ana P. Castaño, Amanda A. Bouffard, Irene Scarfò, Michael C. Kann, Andrea Schmidts, Kathleen Gallagher, Marcela V. Maus	3
16	Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma 2019 ·Blood Advances ·Andrea Schmidts, Maria Ormhøj, Bryan D. Choi, Allison Taylor, Amanda A. Bouffard, Irene Scarfò, Rebecca C. Larson, Matthew J. Frigault, Kathleen Gallagher, Ana P. Castaño, Lauren S. Riley, Maria L. Cabral, Angela C. Boroughs, Rubí M.-H. Velasco Cárdenas, Wolfgang W. Schamel, Jing Zhou, Sean Mackay, Yu‐Tzu Tai, Kenneth C. Anderson, Marcela V. Maus	85
17	CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity breakdown → 2019 ·Nature Biotechnology ·Bryan D. Choi, Xiaoling Yu, Ana P. Castaño, Amanda A. Bouffard, Andrea Schmidts, Rebecca C. Larson, Stefanie R. Bailey, Angela C. Boroughs, Matthew J. Frigault, Mark B. Leick, Irene Scarfò, Curtis L. Cetrulo, Shadmehr Demehri, Brian V. Nahed, Daniel P. Cahill, Hiroaki Wakimoto, William T. Curry, Bob S. Carter, Marcela V. Maus	426
18	Chimeric antigen receptor costimulation domains modulate human regulatory T cell function 2019 ·JCI Insight ·Angela C. Boroughs, Rebecca C. Larson, Bryan D. Choi, Amanda A. Bouffard, Lauren S. Riley, (unknown), Anupriya S. Kulkarni, Curtis L. Cetrulo, David T. Ting, Bruce R. Blazar, Shadmehr Demehri, Marcela V. Maus	104
19	CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma 2019 ·Journal for ImmunoTherapy of Cancer ·Bryan D. Choi, Xiaoling Yu, Ana P. Castaño, Henia Darr, (unknown), Amanda A. Bouffard, Rebecca C. Larson, Irene Scarfò, Stefanie R. Bailey, Genevieve M. Gerhard, Matthew J. Frigault, Mark B. Leick, Andrea Schmidts, Jason Sagert, William T. Curry, Bob S. Carter, Marcela V. Maus	228
20	Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas 2018 ·Blood ·Irene Scarfò, Maria Ormhøj, Matthew J. Frigault, Ana P. Castaño, Selena Lorrey, Amanda A. Bouffard, Alexandria Van Scoyk, Scott J. Rodig, (unknown), Jon C. Aster, Frederic I. Preffer, David M. Weinstock, Marcela V. Maus	105

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact